Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 6Phase 3 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 26Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Prostatic Neoplasms 8Multiple Myeloma 8Lung Neoplasms 7Melanoma 5Leukemia, Myeloid, Acute 5Neoplasm Metastasis 4Glioma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Tuberous Sclerosis 3Stomach Neoplasms 3Sarcoma 3Papillomavirus Infections 3Leiomyoma 3Hematologic Neoplasms 3Glioblastoma 3Carcinoma, Renal Cell 3Venous Thromboembolism 2Rectal Neoplasms 2Polycythemia Vera 2Pain 2Ovarian Neoplasms 2Oligodendroglioma 2Obesity 2Neoplasms by Site 2Myasthenia Gravis 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

olaparib 1enzalutamide 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Metastatic Castration-resistant Prostate Cancer × 90 days × Clear all
NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡